Laparoscopic Revision for Weight Loss Failure After Roux-en-Y Gastric Bypass Using a Modified Distalization Technique

Videoscopy ◽  
2017 ◽  
Vol 27 (1) ◽  
Author(s):  
Theodoros Thomopoulos ◽  
Maximilien Thoma ◽  
Nicolas Jabbour ◽  
Benoit Navez
2010 ◽  
Vol 6 (3) ◽  
pp. S19
Author(s):  
Katayun Irani ◽  
Heekoung A. Youn ◽  
Christine J. Ren-Fielding ◽  
George A. Fielding ◽  
Marina Kurian

2017 ◽  
Vol 28 (2) ◽  
pp. 364-368 ◽  
Author(s):  
Nadav Nevo ◽  
Subhi Abu-Abeid ◽  
Guy Lahat ◽  
Joseph Klausner ◽  
Shai M. Eldar

2015 ◽  
Vol 25 (4) ◽  
pp. 744-749 ◽  
Author(s):  
Felipe León ◽  
Cristóbal Maiz ◽  
David Daroch ◽  
Nicolás Quezada ◽  
Mauricio Gabrielli ◽  
...  

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e037576
Author(s):  
Maud Robert ◽  
Tigran Poghosyan ◽  
Dominique Delaunay ◽  
Elise Pelascini ◽  
Sylvain Iceta ◽  
...  

IntroductionDespite the non-negligible weight loss failure rate at midterm, Roux-en-Y gastric bypass (RYGB) remains the reference procedure in the treatment of morbid obesity with metabolic comorbidities. A recently emerged procedure, the single anastomosis duodeno–ileal bypass with sleeve gastrectomy (SADI-S), could be more effective on weight loss with similar morbidity and lower weight loss failure rate than RYGB. We propose the first randomised, open, multicentre superiority trial comparing the SADI-S to RYGB (SADISLEEVE).Methods and analysisThe main objective is to demonstrate the superiority at 2 years after surgery of the SADI-S compared with RYGB in term of excess weight loss percentage. The secondary objectives are the evaluation of nutritional status, metabolic outcomes, overall complication rates and quality of life, within 2 years after surgery. Key inclusion criteria are obese patients with body mass index (BMI) ≥40 kg/m2 or ≥35 kg/m2 with at least one comorbid condition and candidate to a first bariatric procedure or after failure of sleeve gastrectomy. Patients randomised by minimisation in two arms, based on centre, surgery as a revisional procedure, presence of type 2 diabetes and BMI >50 kg/m2 will be included over 2 years.A sample size of 166 patients in each group will have a power of 90% to detect a probability of 0.603 that excess weight loss in the RYGB arm is less than excess weight loss in the SADI-S arm with a 5% two-sided significance level. With a drop-out rate of 10%, it will be necessary to include 183 patients per group.Ethics and disseminationThe study was approved by Institutional Review Board of Centre Hospitalier Universitaire Morvan (CPP1089-HPS1). Study was also approved by the French national agency for drug safety (2018061500148). Results will be reported in peer-reviewed scientific journals.Trial registration numberNCT03610256.


Sign in / Sign up

Export Citation Format

Share Document